...
首页> 外文期刊>International journal of clinical rheumatology. >Variability in clinical and biological response to rituximab in autoimmune diseases: An opportunity for personalized therapy?
【24h】

Variability in clinical and biological response to rituximab in autoimmune diseases: An opportunity for personalized therapy?

机译:在自身免疫性疾病中对利妥昔单抗的临床和生物学反应的变异性:个性化治疗的机会吗?

获取原文
获取原文并翻译 | 示例
           

摘要

A better understanding of the variability in clinical response to B-cell-depletion therapy using rituximab in rheumatoid arthritis and systemic lupus erythematosus is important to optimize the use of this therapy and improve patient outcomes. To this end, we review current evidence on factors that affect pharmacokinetics and pharmacodynamics of rituximab, and the biological and clinical response to this drug. Also we briefly describe variability in B-cell depletion and reconstitution following rituximab treatment and summarize elements that have been shown to distinguish responders and nonresponders. Finally, we speculate on the prospects for exploiting the knowledge gained thus far in developing rituximab-based personalized therapy for rheumatoid arthritis and systemic lupus erythematosus.
机译:更好地了解使用利妥昔单抗治疗类风湿性关节炎和系统性红斑狼疮对B细胞耗竭疗法的临床反应的变异性,对于优化这种疗法的使用和改善患者预后至关重要。为此,我们回顾了影响利妥昔单抗药代动力学和药效学的因素以及对该药物的生物学和临床反应的现有证据。我们还简要描述了利妥昔单抗治疗后B细胞耗竭和重构的变异性,并总结了已显示出区分反应者和非反应者的要素。最后,我们推测了利用迄今为止在开发基于利妥昔单抗的类风湿性关节炎和系统性红斑狼疮个性化治疗中获得的知识的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号